Evidence map›Paper›PMID 33228686›Full record

ArticleRetrovirology2020

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents.

Thomas Vollbrecht, Aaron O Angerstein, Bryson Menke, Nikesh M Kumar, Michelli Faria de Oliveira, Douglas D Richman, John C Guatelli

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. HCV-specific CD4EBioMedicine · 2026
    Article
  2. Proviruses in CD4Science translational medicine · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Thomas VollbrechtDepartment of Medicine, University of California San Diego, La Jolla, CA, USA. tvollbrecht@health.ucsd.edu.ORCID 0000-0003-1151-8844
Aaron O AngersteinDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Bryson MenkeVA San Diego Healthcare System, San Diego, CA, USA.
Nikesh M KumarDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Michelli Faria de OliveiraDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Douglas D RichmanDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
John C GuatelliDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
University of California San Diego · USVA San Diego Healthcare System · US

Funding

First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
Comparative Study of Molecular Signatures in HIV-Related Neuropathogenesis and Alzheimer's DiseaseR01AG061066 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GALASKO, DOUGLAS R · 2018 to 2022
$3.8M
Activating Latently Infected Cells Using Specific Antigens Including Those of HIV-1R33AI116194 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GUATELLI, JOHN C. · 2018 to 2020
$1.2M
NIAID NIH HHS R33 AI116194NIA NIH HHS R01 AG061066NIA NIH HHS R01AG061066
6 · The paper itself

Abstract

backgroundA reservoir of replication-competent but latent virus is the main obstacle to a cure for HIV-1 infection. Much of this reservoir resides in memory CD4 T cells. We hypothesized that these cells can be reactivated with antigens from HIV-1 and other common pathogens to reverse latency.

resultsWe obtained mononuclear cells from the peripheral blood of antiretroviral-treated patients with suppressed viremia. We tested pools of peptides and proteins derived from HIV-1 and from other pathogens including CMV for their ability to reverse latency ex vivo by activation of memory responses. We assessed activation of the CD4 T cells by measuring the up-regulation of cell-surface CD69. We assessed HIV-1 expression using two assays: a real-time PCR assay for virion-associated viral RNA and a droplet digital PCR assay for cell-associated, multiply spliced viral mRNA. Reversal of latency occurred in a minority of cells from some participants, but no single antigen induced HIV-1 expression ex vivo consistently. When reversal of latency was induced by a specific peptide pool or protein, the extent was proportionally greater than that of T cell activation.

conclusionsIn this group of patients in whom antiretroviral therapy was started during chronic infection, the latent reservoir does not appear to consistently reside in CD4 T cells of a predominant antigen-specificity. Peptide-antigens reversed HIV-1 latency ex vivo with modest and variable activity. When latency was reversed by specific peptides or proteins, it was proportionally greater than the extent of T cell activation, suggesting partial enrichment of the latent reservoir in cells of specific antigen-reactivity.

Indexed as

AdultAgedAntigen PresentationAntigensCD4-Positive T-LymphocytesDendritic CellsFemaleHIV-1HIV InfectionsHumansImmunologic MemoryInterferon-gammaMaleMiddle AgedMuromegalovirusRNA, MessengerAntigensIFNG protein, humanInterferon-gammaRNA, MessengerRNA, ViralAntigenCD4 T cellHIV-1Latency

Identifiers

PMID33228686
PMCPMC7684880
OpenAlexW3110259709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.